Loading

Slzii.com Search

Search (News)

Olatorepatide Obesity Treatment Licensed By Regeneron Demonstrates Positive Phase 3 Results In Chinese Patients

health top

(MENAFN - GlobeNewsWire - Nasdaq) Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron's global Phase 3 registrational program to be initiated later this ...
2026-03-09 07:16:26

What are you doing?

0.067866086959839


News
News

Latest News and Headlines
(MENAFN - GlobeNewsWire - Nasdaq) Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron's global Phas...
News